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Abstract: Background: Epidermal growth factor receptor (EGFR) inhibitors can cause serious
cutaneous toxicities, including pruritus and papulopustular acneiform skin eruptions. Increasingly,
the neurokinin-1 receptor (NK1R) antagonist aprepitant is being utilized as an anti-pruritic agent
in the treatment of EGFR-inhibitor induced pruritus. Aprepitant is believed to reduce itching by
blocking NK1R on the surface of dermal mast cells. However, the eﬀects of aprepitant on human
keratinocytes remains unexplored. Methods: Herein, we examine the eﬀects of aprepitant on EGFR
stimulation in HaCaT cells using a phosphoproteomic approach including reverse phase protein
arrays and Ingenuity Pathway Analysis. Changes in EGFR phosphorylation were visualized using
Western blotting and the eﬀect of EGF and aprepitant on the growth of HaCaT cells was determined
using the WST-1 Cell Proliferation Assay System. Results: We found that aprepitant increased the
phosphorylation of EGFR, as well as 10 of the 23 intracellular proteins phosphorylated by EGF.
Analysis of phosphoproteomic data using Ingenuity Pathway Analysis software revealed that 5 of
the top 10 pathways activated by EGF and aprepitant are shared. Conclusions: We propose that
aprepitant produces its antipruritic eﬀects by partially activating EGFR. Activation of EGFR by
aprepitant was also seen in primary human keratinocytes. In addition to itch reduction through
partial activation of shared EGFR pathways, aprepitant exerts a dose-dependent cytotoxicity to
epithelial cells, which may contribute to its antitumor eﬀects.
Keywords: aprepitant; erlotinib; pruritus; EGFR; epidermal growth factor receptor; NK1R;
neurokinin1-receptor

1. Introduction
Epidermal growth factor receptor (EGFR) inhibitors such as erlotinib can cause serious cutaneous
toxicities, including papulopustular acneiform skin eruptions and severe pruritus [1–3]. The skin
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toxicity of EGFR inhibitors is due to the blockade of EGFR in the epidermis, which was demonstrated
by genetic ablation of epidermal EGFR in a mouse model [4]. Similarly, a loss-of-function mutation
of EGFR in a human child exhibited skin toxicity resembling that seen in patients taking EGFR
inhibitors [5].
The eﬀects of erlotinib-induced pruritus on quality of life is substantial; 12–16% of all cancer
patients treated with erlotinib develop pruritus, usually within the ﬁrst few days to weeks of therapy [6].
In addition to its signiﬁcant eﬀect on psychosocial well-being, pruritus can also interfere with treatment
eﬃcacy by leading to poor drug compliance and even dose modiﬁcations or discontinuation by
healthcare providers [1,7]. A survey of oncologists from 2010 revealed that 76% of practitioners
modiﬁed a patient’s dose of EGFR inhibitors in response to the associated skin toxicities, and 32%
discontinued EGFR inhibitor therapy altogether [8]. Thus, understanding and preventing EGFR
inhibitor skin toxicity is critical to improving patient quality of life and survival.
In recent years, neurokinin-1 receptor (NK1R) antagonists such as aprepitant have emerged as a
promising class of medications for the treatment of chronic pruritus [9]. In 2009, a case series in the New
England Journal of Medicine ﬁrst described the successful oﬀ-label use of aprepitant to treat severe,
recalcitrant itch in three patients with cutaneous T-cell lymphoma (CTCL) [10]. Since then, a case series
of cancer patients showed prompt relief of erlotinib-induced itch after administration of aprepitant [11].
Furthermore, a clinical trial in 2012 established the eﬃcacy of aprepitant in reducing pruritus caused
by anti-EGFR therapy [12]. The current proposed mechanism for aprepitant’s antipruritic eﬀect is
the prevention of the neuropeptide substance P (SP) from binding to NK1R on the surface of dermal
mast cells, thus preventing mast cell activation and degranulation [13]. However, this theory remains
unconﬁrmed, and the eﬀect of aprepitant on human keratinocytes remains largely unexplored.
To better understand the eﬀect of aprepitant on human keratinocytes, we examined the eﬀects of
aprepitant on EGFR signaling in HaCaT cells—an immortalized line of human keratinocytes [14]—using
reverse phase protein array (RPPA) technology.
2. Materials and Methods
Human HaCaT keratinocytes cells were obtained from Dr. Xiao-Fan Wang, Duke University, and
were cultured in Dulbecco’s modiﬁed Eagle’s medium (DMEM) (Gibco Cat #11960-044), supplemented
with 10% fetal bovine serum (FBS) (Sigma, cat #F2442) and 1% L-glutamine (Ionza, cat #17-605E). The
HaCaT cell line was authenticated by short tandem repeat (STR) DNA proﬁling using the Promega
GenePrint 10 kit (Promega Cat #B9510) by the Duke University DNA Analysis Facility. The observed
STR proﬁle was Amelogenin: (X,Y); CSF1PO: (11,11); D13S317: (11,12); D16S539: (9,9); D5S818: (12,12);
D7S820: (9,11); TH01: (9.3,9.3); TPOX: (8,12); vWA: (15,15); D21S11: (28,29). Normal Human Epidermal
Keratinocytes (NHEK), isolated from the skin of a 23-year-old female, were purchased from PromoCell
GmbH, Heidelberg, Germany (cat #C-12003; lot #401Z028.1). These cells were grown in the media
provided by the manufacturer. Primary antibodies to detect total EGFR (cat #2232), EGFR-pY1068
(cat #2234), goat anti-rabbit (cat #7074), and anti-biotin (cat #7075) were purchased from Cell Signaling
Technology. Aprepitant was purchased from APExBIO, Houston, TX (cat #A1684). Substance P and
epidermal growth factor (EGF) were obtained from Sigma (St. Louis, MO). Human insulin-like growth
factor-1 (IGF-1) was purchased from Gibco/ThermoFisher (cat #PHG0078). Erlotinib hydrochloride
(cat #E-4007) was purchased from LC laboratories (Woburn, MA, USA).
2.1. Preparation of HaCaT Cells for RPPA Analysis
HaCaT cells (5 × 105 ) were placed in each well of a six-well plate. The next day, the medium
was changed to serum-free. After 24 h in serum-free media, the cells were treated with various drugs.
To examine the stimulation of EGFR by EGF, the cells were treated with EGF (100 ng/mL) for 10 min.
To examine the blockade of EGF stimulation of EGFR by erlotinib, the cells were treated with erlotinib
for 1 h followed by 10 min of exposure to EGF. To study the stimulation of EGFR with aprepitant and
other NK1R blockers, cells were treated with these drugs for 1 h. After the treatment, the media was
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removed and the cells were washed twice with ice-cold PBS. The washed cells were taken in 120 μL
of RPPA lysis buﬀer (1% Triton X-100, 50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
(HEPES) pH 7.4, 150 mM NaCl, 1.5 mM MgCl2 , 1 mM egtazic acid (EGTA), 100 mM NaF, 10 mM Na
pyrophosphate, 1 mM Na3 VO4 , 10% glycerol, plus a cocktail of protease and phosphatase inhibitors
(recipe provided by M.D. Anderson’s Reverse Phase Protein Array core facility)), centrifuged, and
processed according to the instructions provided by the RPPA core facility [15].
2.2. Ingenuity Pathway Analysis of RPPA Data
Ingenuity pathway analysis (IPA) suite (Qiagen, Germany) was separately run on RPPA data from
cells treated with EGF and aprepitant. The top ten canonical pathways aﬀected (ranked by p value
from Fisher’s exact test) by these treatments were determined. The “threshold” (vertical dotted line)
shows a p value of 0.05. The “ratio” (line with points on each bar) refers to the proportion of molecules
in the dataset that mapped to IPA’s canonical pathway.
2.3. Western Blotting
Changes in EGFR phosphorylation in HaCaT cells and NHEK primary keratinocytes were
visualized using Western blotting (Figure 1A–D) as described previously [15]. Brieﬂy, approximately
500,000 freshly dissociated HaCaT or primary keratinocytes were plated in six-well plates containing
5 mL of media. After 24 h, the media was changed to 5 mL of serum-free media and cells were incubated
for one hour with dimethylsulfoxide (DMSO) (control and EGF groups) or with diﬀerent concentrations
of aprepitant in DMSO in a 37 ◦ C, 5% CO2 incubator. After this incubation, the cells in one well
(EGF group) were treated with 5 μL of 100 μg/mL EGF for 10 min. The media was removed from all
wells and cells were washed twice with ice-cold PBS. The washed cell pellets were added to 100 μL of
RPPA lysis buﬀer and the protein concentration was measured, as detailed previously [15]. About 10 μg
of lysate proteins from each treatment group was run on a 4–12% NovexBis-Tris gel (Life Technologies,
Grand Island, NY, USA). The separated proteins were transferred to a polyvinylidene diﬂuoride
membrane, blocked with 5% milk, then probed with a rabbit polyclonal p-EGFR Y1068 antibody
(catalog #2234; Cell Signaling Technology, Beverly, MA, USA) or a rabbit polyclonal EGFR antibody
to detect total EGFR. Rabbit Beta-Actin antibody was used to show equal protein loading. The blot
was developed using the Pierce Enhanced Chemiluminescence (ECL) Western Blotting Substrate Kit
(cat #32106, ThermoFisher Scientiﬁc, Waltham, MA, USA) and Biomax MR ﬁlm (Sigma-Aldrich Corp.,
St. Louis, MO, USA).
2.4. Eﬀect of EGF and Aprepitant on the Growth of HaCaT Cells
The eﬀect of EGF and aprepitant on the growth of HaCaT cells was determined using the WST-1
Cell Proliferation Assay System according to the manufacturer’s instructions (cat #MK400Takara Bio
USA; Mountainview, CA). Brieﬂy, freshly dissociated HaCaT cells were seeded in a 96-well plate at a
density of 2000–5000 cells/well in 200 μL of media. The plates were placed in a cell culture incubator
(37 ◦ C, 5% CO2 ) overnight and the media was changed to serum-free media. After 24 h, cells were
treated with diﬀerent concentrations of EGF (dissolved in PBS) and aprepitant (dissolved in DMSO).
Each concentration of EGF and aprepitant was tested in quadruplicate. After incubating the cells
for 3–4 days in the incubator, 20 μL of WST-1 reagent was added to each well. The cells were again
incubated in the incubator for 1–4 h, and absorbance was measured at a wavelength of 450 nm using
Biorad’s Bench Mark Plus plate reader (Hercules, CA, USA). Background absorbance was measured by
adding the WST-1 reagent to wells containing the media but no cells. The experiment was repeated
four times and the data were analyzed using GraphPad Prism 5.0 software (San Diego, CA, USA).
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Figure 1. Proteomic analysis of HaCaT cells using reverse phase protein array (RPPA) technology.
(A) Unsupervised and supervised heatmaps from RPPA analysis on HaCaT cells treated with the
following agents: Control (DMSO only), EGF (100 ng/mL) for 10 min, IGF-1 (100 ng/mL) for 10 min,
erlotinib (10 μM) for 60 min followed by EGF (100 ng/mL) for 10 min, erlotinib (10 μM) for 60 min
followed by IGF-1 (100 ng/mL) for 10 min, aprepitant (10 μM) for 60 min. (B) A section of heatmap
focusing on intracellular proteins phosphorylated by epidermal growth factor receptor (EGFR) activation.
(C) List of 23 phosphoproteins whose phosphorylation increased by more than 20% upon stimulation
of EGFR by EGF. Phosphorylation of 10 of these proteins (43% of the total phosphorylated upon EGF
stimulation) also increased following treatment with aprepitant (marked with an asterisk). (D) Top 10
pathways determined by Ingenuity Pathway Analysis of RPPA data from control and EGF-stimulated
HaCaT cells. (E). Top 10 pathways determined by Ingenuity Pathway Analysis of RPPA data from
control and aprepitant-treated HaCaT cells.

3. Results
Figure 1A show shows the results of RPPA analysis on HaCaT cell lysates treated with the
following conditions: Control, EGF, IGF-1, erlotinib followed by EGF, erlotinib followed by IGF-1, and
aprepitant. Figure 1B shows the RPPA analysis results with a focus on the intracellular proteins that
were phosphorylated by EGFR activation. Figure 1C lists the HaCaT human keratinocyte proteins
whose phosphorylation increased by at least 20% upon stimulation by EGF. The EGF-induced increase
in the phosphorylation of these proteins (Figure 1C, column 2) was mediated through EGFR, because no
increase in phosphorylation was seen with EGF when the cells were pre-treated with the EGFR-tyrosine
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kinase inhibitor (TKI) erlotinib (Figure 1C, column 3). Figure 1C, column 4 shows HaCaT cell proteins
whose phosphorylation was increased when exposed to aprepitant. Proteins marked with an asterisk
demonstrated an increase in phosphorylation. As can be seen, 10 out of 23 proteins phosphorylated by
EGF stimulation were also phosphorylated by aprepitant, albeit not as robustly as EGF. These data
indicate that aprepitant in HaCaT cells serves as a partial agonist of EGFR. Interestingly, cross-talk
between EGFR and NK1R was also reported in human mesenteric preadipocytes, but in these cells
EGFR phosphorylation was increased by substance P (SP), an agonist of NK1R [16]. There are additional
examples of SP increasing the phosphorylation of EGFR [17,18]. However, none of these reports
came from keratinocytes. To our knowledge, the keratinocyte is the only cell type where EGFR
phosphorylation is increased by an NK1R antagonist. The mechanism by which NK1R blockade,
rather than stimulation, in keratinocytes increases EGFR phosphorylation remains to be determined.
However, our preliminary data indicate that keratinocytes express only the truncated isoform of NK1R
(Kwatra et al., unpublished data).
We also treated HaCaT cells with IGF-1, because IGF-1 was implicated in the transmodulation
of EGFR in keratinocytes [19]. As expected, IGF-1 stimulation of HaCaT cells increased the
phosphorylation of IGF-1R at Y1135 and Y1137 (last row in Figure 1C) indicating that IGF-1R
in HaCaT cells was functional. IGF-1 also increased the phosphorylation of EGFR (visualized in
columns 1 and 5). Further, IGF-1 increased the phosphorylation of p90RSK_T543, which was blocked
by erlotinib. Thus, our data showed that a downstream kinase of EGFR signaling was activated by
IGF-1 and was blocked by erlotinib. Taken together, our results provide direct evidence of IGF-1
activation of EGFR in keratinocytes, which was suggested by previous reports [16]. However, the
increase in EGFR signaling by IGF-1 was much less than that seen with aprepitant (compare columns 4
and 5).
To obtain further insight into aprepitant’s mechanism of action, Ingenuity Pathway Analysis
software was used to compare the top ten pathways activated by EGF (Figure 1D) and aprepitant
(Figure 1E). These data show that ﬁve of the top ten signaling pathways activated by EGF and aprepitant
are shared: ErbB, Pancreatic Adenocarcinoma, Neuregulin, Molecular Mechanisms of Cancer, and p53.
To conﬁrm the observed aprepitant-induced increase in EGFR phosphorylation seen with RPPA
analysis (Figure 1C), Western blotting was utilized (Figure 2). As Figure 2A shows, aprepitant increased
the phosphorylation of EGFR in a dose-dependent manner. Note that the antibody that was used
for total EGFR (catalog #2232, Cell Signaling Technology, Danvers, MA, USA) was raised against a
peptide from an EGFR sequence that included Y1068; therefore, it did not recognize EGFR when it was
phosphorylated at Y1068 (this explains why we had a weaker band for total EGFR when the receptor
was phosphorylated).
We next examined whether aprepitant-induced EGFR activation seen in HaCaT cells, a cell line
derived from human keratinocytes, was also seen in primary human keratinocytes (NHEK) cells.
As Figure 2B shows, aprepitant also stimulated the phosphorylation of EGFR in NHEK cells in a
dose-dependent manner.
Finally, the eﬀects of aprepitant on cell division, as measured by the WST-1 Cell Proliferation Assay,
were tested by incubating HaCaT cells with diﬀerent concentrations of aprepitant and EGF, respectively.
As expected, HaCaT cells demonstrated a signiﬁcant dose-dependent increase in cell proliferation upon
incubation with EGF as compared to PBS (Figure 3A). In contrast, HaCaT cells showed a signiﬁcant
dose-dependent cell death with increasing concentrations of aprepitant (Figure 3B).

Medicines 2019, 6, 114

6 of 8

$

%



Figure 2. Visualization of EGFR phosphorylation at Y1068 by Western blotting. (A) HaCaT cells were
treated with diﬀerent concentrations of aprepitant. Western blot analysis showed that aprepitant
stimulated the phosphorylation of EGFR in a dose-dependent manner. (B) Normal Human Epidermal
Keratinocytes (NHEK) cells were treated with diﬀerent concentrations of aprepitant. Western blot
analysis showed that aprepitant increased the phosphorylation of EGFR in primary keratinocytes in a
dose-dependent manner, similar to that seen in HaCaT cells.

Figure 3. Eﬀects of EGF and aprepitant on growth of HaCaT Cells. (A) HaCaT cells treated with
EGF showed a signiﬁcant dose-dependent increase in cell proliferation compared to incubation
with PBS alone. (B) HaCaT cells treated with aprepitant (AP) showed a signiﬁcant dose-dependent
signiﬁcant increase in cell death compared to incubation with DMSO alone. (* indicates p < 0.05,
** indicates p < 0.01).

4. Discussion
A key ﬁnding of our study was that aprepitant activated EGFR in human keratinocytes, a novel
ﬁnding that may explain aprepitant’s anti-pruritic activity. Despite partial activation of EGFR in
keratinocytes, aprepitant also demonstrated dose-dependent cytotoxicity to epithelial cells in our study
that was consistent with previous reports of its anti-tumor eﬀects [20–22]. One hypothesis for this
phenomenon is that the truncated form of NK1R may predominate in human skin, in addition to
being overexpressed in tumor cells. In contrast, the full-length form of NK1R is typically expressed in
normal non-tumor cells. This diﬀerence may explain the dose-dependent toxicity of aprepitant that
was observed in HaCaT cells. It should be noted, however, that aprepitant-induced cytotoxicity should
be negligible at doses lower than 10 μM that are used for anti-pruritic eﬀects.
The cutaneous reactions seen in erlotinib-treated patients appear to be clinical indicators of
treatment response, with the severity of cutaneous toxicities also appearing to be dose-dependent [6,23].
There is also a strong positive correlation between the severity of cutaneous toxicity following EGFR
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inhibition and overall patient survival [24]. Thus, despite the adverse eﬀects on quality of life and
compliance, the presence of cutaneous symptoms in these cancer patients may be viewed as a positive
event. Therefore, aprepitant may be recommended as a therapeutic option for management of
EGFR-TKI-induced itch [4].
The pathophysiology of tyrosine-kinase inhibitor-induced pruritus is incompletely understood,
and data studying this phenomenon are sparse [23]. It is important to understand the mechanism
underlying EGFR inhibitor-induced pruritus and skin toxicity to prevent premature termination of
chemotherapy and to improve quality of life in cancer patients. Future studies should be directed at
further understanding the mechanism of EGFR-TKI-induced pruritus and skin toxicity in order to
better develop pharmacotherapies to relieve symptoms without interfering with cancer treatment.
In summary, our ﬁndings demonstrated that aprepitant activated EGFR in human keratinocytes by
interacting with NK1R, and this might be the mechanism by which aprepitant reduces erlotinib-induced
pruritus and skin toxicity.
We also showed that, in addition to partial activation of EGFR that may mediate its antipruritic
eﬀects, aprepitant also displayed antitumoral eﬀects in suppressing cell growth. Future research on
EGFR signaling and skin cytotoxicity in patients receiving the U.S. Food and Drug Administration
(FDA)-approved doses of aprepitant is needed to verify the eﬀects of aprepitant on human keratinocytes
in vivo.
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